US 10544223
Combination therapy with an anti-axl antibody-drug conjugate
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10544223 (Combination therapy with an anti-axl antibody-drug conjugate) held by ADC THERAPEUTICS SA expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ADC THERAPEUTICS SA
- Grant date
- Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K31/138, A61K31/166